Journal of Asthma最新文献

{"title":"Asthma control, its related factors, and impact on quality of life among pediatric patients at a tertiary center in Jordan: a cross-sectional study.","authors":"Montaha Al-Iede, Khetam Alfaouri, Dana Manzlgi, Layla Nazzal, Toqa Awaisheh, Ola Alsharif, Enas Al-Zayadneh","doi":"10.1080/02770903.2024.2449236","DOIUrl":"10.1080/02770903.2024.2449236","url":null,"abstract":"<p><strong>Introduction: </strong>Pediatric asthma is a common respiratory disease that burdens affected patients, their caregivers, and the entire healthcare system. Uncontrolled asthma ultimately impacts patients' quality of life. There are limited studies examining the factors associated with asthma control and quality of life. Thus, this study aimed to explore factors associated with asthma control and examine the relationship between asthma control and quality of life in children with asthma.</p><p><strong>Methods: </strong>A cross-sectional study was conducted from October 2023 to January 2024 at the Jordan University Hospital, including 136 children aged 7-17 diagnosed with asthma. Asthma control was assessed using the Asthma Control Test (ACT) or Childhood Asthma Control Test (C-ACT). Medication adherence was measured using the 8-item Morisky Medication Adherence Scale (MMAS), and quality of life was evaluated using the Pediatric Asthma Quality of Life Questionnaire (PAQLQ).</p><p><strong>Results: </strong>Only 43.4% of patients had proper asthma control. The average quality of life and MMAS scores were 4.9 ± 1.5 and 4.2 ± 1.9, respectively. Uncontrolled asthma was associated with increased hospital admissions (<i>p</i> = 0.008), sensitivity to cold (<i>p</i> = 0.002), spring weather (<i>p</i> = 0.031), and infections (<i>p</i> = 0.001). Patients with controlled asthma had significantly higher quality of life (<i>p</i> < 0.001), but no significant differences in MMAS scores (<i>p</i> = 0.743). On multivariate analysis, QoL score was a positive predictor of control (<i>p</i> < 0.001), while sensitivity to infections were a negative predictor (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Most pediatric patients with asthma at the Jordan University Hospital had poor asthma control. Quality of life remained a positive predictor of control irrespective of adherence to asthma treatment. This highlights the need for caregivers and physicians to focus greater attention on these cases, given the substantial clinical and social challanages they poses for affected children.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"945-953"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between dietary flavonoids and childhood asthma.","authors":"Li Ling, Hongbo Shi","doi":"10.1080/02770903.2024.2449242","DOIUrl":"10.1080/02770903.2024.2449242","url":null,"abstract":"<p><strong>Objective: </strong>Dietary flavonoids in various green plants have anti-inflammatory, antioxidant, and immune-modulating properties. While numerous studies have confirmed that flavonoid substances benefit asthma, evidence remains limited in epidemiological research and human experiments. This study aimed to explore the relationship between childhood asthma and dietary flavonoids.</p><p><strong>Methods: </strong>Dietary flavonoids comprise isoflavones, anthocyanins, flavan-3-ols, flavanones, flavones, and flavonols. This study used data from the United States National Health and Nutrition Examination Survey, collected during interviews from 2007 to 2010 and 2017 to 2018. Asthma data were obtained from the survey questionnaire. The analysis included 7,913 participants under 20 years old. A multivariable logistic regression model was performed to investigate the correlation between flavonoids (as constant or category variables) and asthma frequency among children in the United States, with stratified analyses performed for each group.</p><p><strong>Results: </strong>After adjusting for potential confounding variables, a significant negative correlation was observed between asthma incidence and the highest intake group of anthocyanins compared to the lowest intake group (odds ratio [OR] = 0.83, 95% confidence interval [CI]: 0.72-0.97, and <i>p</i> = 0.0182). Similarly, asthma incidence indicated a significant negative association with the median flavonol intake group compared to the lowest intake group (OR = 0.83, 95% CI: 0.72-0.97, and <i>p</i> = 0.0165). In the stratified analysis, anthocyanin content demonstrated a significant negative correlation with asthma prevalence among males, non-Hispanic whites, nonsmoking families, and middle-income families (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The intake of dietary flavonoids, including anthocyanins and flavonols, is correlated with asthma prevalence in children.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"954-961"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult patients with an exacerbation of asthma and a higher risk for pulmonary embolism: a cluster analysis.","authors":"Javad Sadeghi, Neda Esfandiari, Babak Mohammadi","doi":"10.1080/02770903.2025.2458509","DOIUrl":"10.1080/02770903.2025.2458509","url":null,"abstract":"<p><strong>Objective: </strong>Current literature acknowledges the complexity of exacerbation triggers in patients with asthma. We studied the clinical heterogeneity of patients with asthma exacerbation suspected of having pulmonary embolism using cluster analysis and compared the clusters regarding of the risks for pulmonary embolism.</p><p><strong>Methods: </strong>In a secondary analysis of a dataset from the University of Florida, USA, individuals who experienced asthma exacerbation between June 2011 and October 2018 were included. All patients had undergone pulmonary CT angiography. Overall, 18 variables consisting of demographic, clinical, comorbidity, and therapeutic characteristics were used to cluster patients. The clusters were then profiled and compared in the percentages of pulmonary embolism.</p><p><strong>Results: </strong>In total, 758 patients (226; 29.8% men) with an exacerbation of asthma were included in the analysis. The frequency of a confirmed pulmonary embolism was 145 (19.1%). Two distinct clusters were identified with a statistically significant difference in pulmonary embolism [<i>p</i> < 0.001, odds ratio (95%CI)=2.24 (1.55, 3.24)]. We developed a high-performance classifier to profile the low- and high-risk clusters (area under the curve = 0.923, positive likelihood ratio = 20.2). The three top important variables discriminating the two clusters were age, heart rate, and body mass index. Older age, lower heart rate, higher body mass index, black race, and positive medical history (including atrial fibrillation) were more frequent in the high-risk group. Despite the higher percentage of women in the high-risk group, the sex ratios were not significantly different between the clusters.</p><p><strong>Conclusion: </strong>There are two clusters in patients with an exacerbation of asthma with different prognoses percentages of pulmonary embolism. The clusters can be well identified based on patient characteristics.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1052-1060"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of Fluticasone Furoate/Umeclidinium/vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma, a randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study.","authors":"Etsuko Tagaya, Jun Shinada, Hiroyuki Nagase, Junko Terada-Hirashima, Masayuki Hojo, Naruhiko Sugihara, Osamitsu Yagi, Mayoko Tsuji, Tomohiro Akaba, Katsunori Masaki, Koichi Fukunaga, Hiroyuki Ohbayashi, Kaoru Chiba, Soichiro Hozawa, Ryo Atsuta, Yasuhiro Aoki, Hisato Hiranuma, Yasuhiro Gon, Akihiko Tanaka","doi":"10.1080/02770903.2025.2455416","DOIUrl":"10.1080/02770903.2025.2455416","url":null,"abstract":"<p><strong>Background: </strong>Persistent cough bothers many patients with asthma because it worsens their quality of life; therefore, it must be remedied immediately. The efficacy of triple therapy as a first-line treatment for cough remains unclear. To evaluate the effectiveness and safety of the triple therapy against persistent cough, the clinical effect of regular treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or placebo in adult patients with asthma was investigated.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled, parallel-group multicenter trial recruited asthma patients with persistent cough from hospitals and primary care clinics between June 2022 and December 2023. Participants were randomly given FF/UMEC/VI 200/62.5/25 µg or placebo for 6 wk. The primary endpoint was the average change in the cough symptom score from baseline to week 6. Secondary outcomes were effectiveness on cough-related disease burdens (asthma control questionnaire [ACQ]-5, Leicester cough questionnaire [LCQ] and nighttime awakening). Furthermore, lung function and adverse events were evaluated.</p><p><strong>Results: </strong>The decrease from baseline in the cough symptom score at week 6 was significantly greater in the FF/UMEC/VI group than in the placebo group (<i>p</i> = 0.006). The ACQ-5 scores showed a greater decrease in the FF/UMEC/VI group than in the placebo group. The change from baseline in morning and evening FEV₁ increased in the FF/UMEC/VI group as with the results of peak expiratory flow. No significant adverse events associated with FF/UMEC/VI were noted.</p><p><strong>Conclusions: </strong>In asthma patients with persistent cough, FF/UMEC/VI showed an early response and a significant effect on cough and lung function for 6 wk of treatment.</p><p><p>This study is registered with jRCTs031210412.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1041-1051"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional challenges to optimize the management of patients with severe asthma type 2 inflammation: a Delphi consensus in seven countries.","authors":"Liam G Heaney, Desiree Larenas-Linnemann, Riyad Al-Lehebi, Rodrigo Athanazio, Paulina Barria, Abraham Ali Munive, Daniel Colodenco, Anahi Yañez, Libardo Jimenez, Marcia M Pizzichini, Deepak Talwar, Emilio Pizzichini, Gur Levy, Maria E Laucho-Contreras","doi":"10.1080/02770903.2024.2449233","DOIUrl":"10.1080/02770903.2024.2449233","url":null,"abstract":"<p><p><b>Objective:</b>Severe asthma burdens patients and presents clinical management challenges for healthcare professionals. Biologics are crucial interventions for severe type two (T2) patients with high eosinophil counts. We conducted a Delphi consensus in seven developing or typically underrepresented countries to understand expert agreement on managing severe asthma with type two (T2) inflammation.</p><p><p><b>Methods:</b>The study comprised two online survey rounds and a participant meeting, involving 21 and 20 respiratory experts in the first and second survey, respectively. We developed a 70-statement questionnaire after literature review. Responses were recorded on a Likert scale (0-9) with 75% consensus threshold.</p><p><p><b>Results:</b>Consensus was reached on 37/60 closed-ended questions, including subtypes, in survey-1 and 20/47 closed-ended questions in survey-2. 95% of participants agreed on biomarker use for biologic treatment selection. 100% agreed timely biologic treatment leads to improvement in patients with severe asthma and an eosinophilic phenotype. 90% agreed to avoid maintenance oral corticosteroids (OCS) and start biologic therapy directly. Experts defined clinical remission on treatment as no exacerbations, no OCS use, Asthma Control Questionnaire (ACQ)-5 score < 1.5, and lung function optimization (forced expiratory volume in one second [FEV₁] ≥ 80% of predicted or pre-bronchodilator FEV₁ increase ≥ 100 mL from baseline). In survey-1, 81% agreed these outcomes are achievable in practice. All referral statements achieved consensus.</p><p><p><b>Conclusions:</b>This Delphi study focused on understanding patients with severe asthma and T2 inflammation in developing/underrepresented countries. Appropriately utilizing biomarkers, timely treatment interventions for best outcomes, expert consensus on clinical remission, and referral are crucial for improving patient management.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"929-944"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exacerbation during the first year of treatment affects lung function in subjects with asthma - a 10-year follow-up.","authors":"Pca Almeida, Ev Ponte, R Stelmach, Tw Harrison, N Scichilone, A Souza-Machado, Aa Cruz","doi":"10.1080/02770903.2025.2451690","DOIUrl":"10.1080/02770903.2025.2451690","url":null,"abstract":"<p><strong>Background: </strong>Inhaled corticosteroids (ICS) are the preferred treatment for asthma. They improve symptoms and reduce exacerbations and deaths, but their long-term impact on lung function loss remains unclear, especially after delayed treatment. We aimed to characterize the lung function trajectories in subjects with previously untreated severe asthma. The secondary aim was to identify predictors of FEV₁ decline, and future exacerbations.</p><p><strong>Methods: </strong>This is a <i>post-hoc</i> analysis that followed 184 subjects with asthma for 10 years after a delayed start of regular maintenance ICS treatment. Absolute lung function variation was calculated using two different baselines: (i) FEV₁ after one year of regular treatment (V₁) and (ii) best FEV₁ observed any time before the final visit.</p><p><strong>Results: </strong>Most individuals were female (84%) over 50 years old and had early-onset asthma with a median of 30 years without regular ICS treatment. Ninety-nine (54%) had an FEV1 decline above 25ml/year, using strategy (i). Those subjects were younger, had shorter duration of asthma, and had better lung function at V₁. Most of the participants without any obstructive pattern (74%) or with mild obstruction (64%) at V₁ showed a faster absolute FEV₁ decline, however PRISm showed faster relative decline than the other groups.</p><p><strong>Conclusion: </strong>This study showed improved symptoms and quality of life with variable lung function trajectories among individuals with asthma who start regular treatment after decades of delay. Additionally, exacerbation during the first year was a strong predictor of absolute FEV₁ decline and future exacerbations, while time without treatment was a predictor of relative reduction of FEV₁.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"997-1006"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-biologic FeNO might predict anti-IL-5/IL-5Rα response to treatment in severe asthmatics.","authors":"Bruno Sposato, Marco Scalese, Gianna Camiciottoli, Giovanna Elisiana Carpagnano, Corrado Pelaia, Pierachille Santus, Girolamo Pelaia, Paolo Cameli, Elena Bargagli, Leonardo Gianluca Lacerenza, Dejan Radovanovic, Paola Rogliani, Mauro Maniscalco, Simonetta Masieri, Carlo Cavaliere, Angelo Guido Corsico, Nicola Scichilone, Stefano Baglioni, Antonio Perrella, Pierluigi Paggiaro, Alberto Ricci","doi":"10.1080/02770903.2025.2451691","DOIUrl":"10.1080/02770903.2025.2451691","url":null,"abstract":"<p><strong>Objective: </strong>It remains unclear whether baseline FeNO levels can predict response to anti-IL5/5R biologic treatment in patients with severe asthma.</p><p><strong>Methods: </strong>We recruited 104 patients with severe eosinophilic asthma treated with anti-IL5/anti-IL5R for at least one year who had measured FeNO values before the beginning of anti-eosinophilic treatment. Population was divided into subjects with FeNO < 25 and ≥25 ppb. In each group we evaluated the changes in pulmonary function (FEV₁% and FEF_25-75%), clinical (ACT and exacerbations) and steroid-sparing effect, expressed as the modification of daily dosage of inhaled corticosteroids (ICS) and oral corticosteroids (OC), after anti-IL5/anti-IL5R.</p><p><strong>Results: </strong>FEV₁ changes after treatment were 3.34 ± 15,97% in subjects with low baseline FeNO, whereas 11.2 ± 16.1% in individuals with FeNO ≥ 25 ppb (<i>p</i> = 0.012). Also, FEF_25-75% variations after treatment were different in the two groups: 2.1 ± 10.7% vs 9.6 ± 18% in individuals with FeNO < 25 and ≥25 respectively (<i>p</i> = 0.05). Conversely, ACT (4.4 ± 4.2 vs 5.9 ± 4.6; <i>p</i> = 0.147), exacerbation changes (-2.46 ± 1.5 vs -2.9 ± 1.6; <i>p</i> = 0.137) after treatment were similar in both groups where ICS dosages reduction was alike. On the contrary, the percentage of subjects that reduced/stopped OC treatment after anti-IL5/anti-IL5R was 71.7% in the group with FeNO < 25 ppb whereas 94.1% in individuals with FeNO ≥ 25 (<i>p</i> = 0.06). Multivariate analysis adjusted for all confounding factors also confirmed the relationship between FeNO ≥ 25 and improvement in FEV₁%/FEF_25-75% (β = 8.372, <i>p</i> = 0.013 and β = 8.883; <i>p</i> = 0.062 respectively) and the increased probability of discontinuing/reducing OC use (OR:17.838 [95%CI:3.159-100.730]; <i>p</i> = 0.001) in the high FeNO group.</p><p><strong>Conclusion: </strong>Pre-biologic FeNO might predict a greater response to treatment with anti-IL-5/5R especially in terms of lung function and OC sparing in subjects with severe eosinophilic/allergic asthma. This could likely be a biomarker that can better guide in choosing an anti-IL5/5R in severe overlapping asthma (eosinophilic/allergic) to maximize treatment effects.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1007-1012"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor regarding \"assessing ChatGPT's accuracy and reliability in asthma general knowledge\".","authors":"Simon Høj, Howraman Meteran","doi":"10.1080/02770903.2025.2458525","DOIUrl":"10.1080/02770903.2025.2458525","url":null,"abstract":"","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1092-1093"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and predictors of medication adherence among adolescents and adults with asthma in Ethiopia: a systematic review and meta-analysis.","authors":"Segenet Zewdie, Ewunetie Mekashaw Bayked, Wondim Ayenew, Abyou Seyfu, Assefa Andargie","doi":"10.1080/02770903.2024.2332920","DOIUrl":"10.1080/02770903.2024.2332920","url":null,"abstract":"<p><strong>Objective: </strong>This review aimed to estimate the pooled prevalence and predictors of medication adherence among adolescents and adults with asthma in Ethiopia.</p><p><strong>Data sources: </strong>Primary studies were searched from PubMed, Scopus, HINARI, and Google Scholar from January 1, 2010 to December 10, 2023. In addition, we have used citation tracking.</p><p><strong>Study selections: </strong>Observational studies (cross sectional, case control, and cohort) conducted among asthmatic patients ≥15 years old in Ethiopia, published in English language were included. After screening, the studies were assessed using Joanna Briggs Institute (JBI) critical appraisal tool and data were extracted using a checklist. Heterogeneity was assessed using forest plot, Q-statistics and <i>I</i>².</p><p><strong>Results: </strong>The review was performed among 13 institution-based studies with a total of 2901 participants with asthma. About 1058 participants had comorbid disease and 354 were cigarette smokers. The pooled prevalence of adherence to medications among patients with asthma was 40.50% (95% CI: 28.05, 52.96; <i>p</i> value <i><</i> 0.001) with high heterogeneity (<i>I</i>² = 98.25%, <i>p</i> < 0.001). Getting health education about asthma and having comorbid disease were predictors of medication adherence among adolescents and adults with asthma in Ethiopia.</p><p><strong>Conclusions: </strong>The pooled prevalence of medication adherence among adolescents and adults with asthma in Ethiopia is low and indicated that three out of five adolescents and adults with asthma were non-adherent to medications. This implies the Ministry of Health should develop different strategies to improve medication adherence including patient education and strengthening the health care system. Multicenter longitudinal studies should be further conducted by using objective methods of adherence measurement and large sample size.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"905-918"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between MUC5AC levels in lung and asthma: a meta-analysis based on animal experiments.","authors":"Ju Hui, Liwei Yang, Hang Xu, Ying Zhu, Liting Zhou, Lin Ye","doi":"10.1080/02770903.2024.2449248","DOIUrl":"10.1080/02770903.2024.2449248","url":null,"abstract":"<p><strong>Introduction: </strong>Asthma is one of the severe respiratory diseases and affects the health of people globally. Animal studies have found that the mucin 5ac (Muc5ac) levels in the lung are associated with asthma. This paper aimed to systematically evaluate the relationship between Muc5ac levels in lung and asthma by extracting relevant data from animal experiments.</p><p><strong>Methods: </strong>Literatures published before September 2022 in PubMed, Web of Science, Embase and Cochrane databases were collected. Literatures screening and data extraction were performed according to the criteria and the risks of bias were assessed for the included literatures according to the SYRCLE tool. Type 2 inflammatory asthma model was applied in this paper. Meta-analysis was performed using Stata 16.0 software.</p><p><strong>Results: </strong>A total of 40 publications containing 347 control mice and 337 mice with asthma were included in this study. Meta-analysis results showed the levels of Muc5ac in BALF of mice in asthma group were significantly higher than that in control group [SMD = 3.50, 95%CI(1.45, 5.54)], and the heterogeneity test results showed I2 = 93.0%, <i>p</i> < 0.05. The mRNA expression levels of Muc5ac in lung tissue of mice in asthma group showed a higher level than that in control group [SMD = 4.46, 95%CI (3.38, 5.55)], and the heterogeneity test results showed I2 = 84.3%, <i>p</i> < 0.01. The protein expression levels of Muc5ac in lung tissue of mice in asthma group were significantly higher than those in control group [SMD = 5.70, 95%CI (4.09,7.31)], and the heterogeneity test results showed I2 = 89.7%, <i>p</i> < 0.01.</p><p><strong>Conclusion: </strong>The meta-analysis clarified the positive relationship between Muc5ac in lung and asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"962-974"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}